Exbio — Research products — Antibodies — Nucleus — Anti-p21Waf1 Purified

Anti-p21Waf1 Purified

Regulatory status

RUO

Antigen

p21Waf1

Clone

WA-1

Format

Purified

Reactivity

Human, Non-human primates

Application

ELISA, IHC-P, ICC

Variant

0.1 mg

11-338-C100

In stock

165.00 USD

0.025 mg

11-338-C025

Delivery 1 week

82.50 USD

Variant

0.1 mg

11-338-C100

In stock

165.00 USD

0.025 mg

11-338-C025

Delivery 1 week

82.50 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The antibody WA-1 reacts with p21 protein (Waf1, Cip1, SDI 1; intracellular antigen), a 21 kDa tumour suppressor, which inhibits the activity of cyclin-dependent family kinases and of proliferating cell nuclear antigen.

Application

ELISA, IHC-P, ICC

Application details

Immunohistochemistry (paraffin sections): Positive tissue: colon carcinoma.

Reactivity

Human, Non-human primates

Immunogen

Human p21 protein

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

CDKN1A, CIP1, CAP20

Antigen description

The tumour suppressor p21Waf1 (wild-type p53-activated fragment 1; also known as Cip1, Cdk interacting protein, or SDI 1) is a cyclin-dependent kinase (Cdk) inhibitor, which is expressed by involvement of p53, Egr-1, AP2, STATs or other transcription factors upon various stimuli resulting in cell cycle arrest. Through its N-terminal domain p21Waf1 inhibits Cdk activity, whereas through the C-terminal domain it inhibits the activity of PCNA (proliferating cell nuclear antigen) to activate DNA replication. Cytosolic location of p21 counteracts its inhibitory activities.

Entrez Gene ID 1026

UniProt ID P38936

Immunohistochemistry staining of colon carcinoma (paraffin-embedded sections) with anti-p21 (WA-1).

Immunocytochemistry staining of p21 in human primary fibroblasts using anti-p21 (WA-1; green). Actin cytoskeleton decorated by phalloidin (red) and cell nuclei stained with DAPI (blue).

General references:

Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY: p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res. 2008 Mar 1;68(5):1369-77.
PubMed

Keeshan K, Cotter TG, McKenna SL: Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. Br J Haematol. 2003 Oct;123(1):34-44.
PubMed

Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994 Jun 16;369(6481):574-8.
PubMed

Horky M, Kuchtickova S, Vojtesek B, Kolar F: Induction of cell-cycle inhibitor p21 in rat ventricular myocytes during early postnatal transition from hyperplasia to hypertrophy. Physiol Res. 1997;46(3):233-5.
PubMed

Zhang C, Kavurma MM, Lai A, Khachigian LM: Ets-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21WAF1/Cip1: ETS-1 regulates basal and and inducible p21WAF1/Cip: ETS-1 regulates basal and inducible p21WAF1/Cip1 transcription via distinct cis-acting elements in the p21WAF/Cip1 promoter. J Biol Chem. 2003 Jul 25;278(30):27903-9.
PubMed

Product specific references:

Kolář Z, Murray PG, Scott K, Harrison A, Vojtěšek B, Dušek J: Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer.
PubMed